Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...

Heart failure (HF) guidelines and practice have been quick to embrace the sodium-glucose cotransporter 2 (SGLT2) inhibitor drug class after DAPA-HF, EMPEROR-Reduced, and other trials suggested that, ...

Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI. Using a sodium-glucose cotransport 2 (SGLT2) ...

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes and worsening HF or at CV risk assigned the dual SGLT1/SGLT2 inhibitor sotagliflozin ...

The warnings will address 2 issues: the risk of too much acid in the blood and severe urinary tract infections. The FDA today added warnings to labels of sodium glucose co-transporter-2 (SGLT2) ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to both lower blood pressure and promote weight loss, and they act rather subtly, stated Rudolf de Boer, MD, PhD, clinical ...

Less than a decade ago, the Food and Drug Administration approved drugs for treating type 2 diabetes in an entirely new way. Since that time, evidence in favor of the use of sodium/glucose ...

Overweight or obesity, an unfavorable distribution of fat in the body and the development of type 2 diabetes are often associated with a reduced effect of the hormone insulin in many organs, including ...

Please provide your email address to receive an email when new articles are posted on . Adults with diabetes using SGLT2 inhibitors have lower risks for developing cancers than those who do not use ...